Clinical Trial Update: Cost Effectiveness Of Sunitinib In Central America And Caribbean

View source ↗

Summary

Pfizer-sponsored trial evaluating the cost-effectiveness of sunitinib for metastatic renal cell carcinoma in Central America and the Caribbean was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Renal Cell Carcinoma | Status: TERMINATED